Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 147 clinical trials
Phase II Clinical Trial of Percutaneous Ventricular Restoration Using Heartech® Device Preventing Heart Failure Post Myocardial Infarction (The Partical Study) (Partical)

of the procedure, all-cause mortality, cardiac death, rehospitalization rates and MACCE occurrence rate within 12 month. Besides, left ventricular end systolic volume index (LVESVI) change at 30 days

  • 0 views
  • 24 Feb, 2022
  • 1 location
Impact of NIRS-guided Cardiopulmonary Resuscitation After Cardiac Arrest on Resuscitation Rate (NICA)

Sudden cardiac death is one of the main causes of morbidity and mortality worldwide. Cardiac arrest requires prompt intervention by cardiopulmonary resuscitation (CPR). The resuscitation

oximetry
near-infrared spectroscopy
resuscitation
  • 0 views
  • 24 Apr, 2022
  • 1 location
Deferred Stenting in Patients With Anterior Wall STEMI (INNOVATIONCORE)

failure, recurrent myocardial infarction (MI), target vessel revascularization (TVR) at 2 years. Secondary Endpoints) Clinical events A. All-cause death B. Cardiac death C

coronary angioplasty
clot
chest pain
heart failure
angiography
  • 6 views
  • 01 Feb, 2022
  • 1 location
Role of Perhexiline in Hypertrophic Cardiomyopathy

. Occasionally, the disease may cause sudden cardiac death (SCD). HCM is the most common cause of SCD in young people including competitive athletes. In addition, HCM has been found to result in significant

  • 0 views
  • 19 Mar, 2021
  • 1 location
Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19 (CONTRAST-3)

(LV) contractile function and its volumetric indices; to study the mechanisms of ventriculo-arterial coupling and the influence of autonomic regulation, the role of markers of the sudden cardiac death

q waves
atorvastatin
ischemia
clot
angiography
  • 0 views
  • 27 May, 2022
  • 1 location
Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter

To examine the treatment of coronary de-novo stenosis with a sirolimus coated balloon versus a paclitaxel coated balloon

sirolimus
unstable angina
ischemia
paclitaxel
stenosis
  • 0 views
  • 03 Sep, 2021
  • 4 locations
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Coronary De Novo Lesions

The purpose of this study is to evaluate the safety and efficacy of a novel Paclitaxel-coated balloon (Genoss® DCB) by demonstrating non-inferiority to in-lesion late lumen loss at 6 months after the procedure in Korean patients with coronary de novo lesions compared with a product of the same category (SeQuent® …

unstable angina
stable angina
ischemia
stenosis
angiography
  • 0 views
  • 16 Mar, 2022
  • 1 location
The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries (BIOADAPTOR RCT)

The objective of this study is to verify the safety and efficacy of the investigational device (ELX1805J) for the treatment of ischemic heart disease due to de novo, native coronary artery lesions

coronary angioplasty
unstable angina
heart disease
bypass graft
ischemia
  • 0 views
  • 23 Mar, 2022
  • 2 locations
Pharmacological Reduction of Right Ventricular Enlargement (PROVE)

Functional tricuspid regurgitation (TR) has been regarded as a secondary phenomenon of heart failure (HF), mitral valve (MV) disease or atrial fibrillation. Regardless of left ventricular (LV) function or pulmonary artery pressure, presence of moderate or greater functional TR is associated with poor prognosis. When a patient develops functional TR, …

fibrillation
ejection fraction
regurgitation
  • 0 views
  • 23 Mar, 2022
  • 1 location
Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure (EMMED-HF)

This clinical trial will determine if subjects with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM2) receiving sodium-glucose cotransporter 2 (SGLTi2) inhibitor therapy (ertugliflozin) alters cardiac metabolism compared to placebo in a single blinded (to subject), randomized, parallel group, active controlled, single center experimental design.

  • 0 views
  • 22 Mar, 2022
  • 1 location